Drug Metabolite Identification with a Streamlined Software Workflow

Significance of the topic

Drug metabolite identification is essential for understanding pharmacokinetics, safety and efficacy of new therapeutic compounds. Early-stage drug candidates and their metabolites often lack reference spectra, complicating their detection and structural characterization in biological matrices. A streamlined, integrated workflow addresses these gaps by combining high-resolution mass spectrometry, advanced data analytics and in silico structure prediction.

Objectives and study overview

This study presents a cohesive platform for untargeted metabolite discovery using verapamil as a model compound. Key aims include:

• Developing a sample preparation and injection strategy minimizing manual handling.
• Implementing chemometric filtering to isolate drug-related features from complex microsomal extracts.
• Employing a custom in silico database for novel metabolite identification when spectral libraries are incomplete.

Methodology and instrumentation

Microsomal incubations were performed with human liver microsomes and verapamil at 5 µM over seven time points (0–180 min) in a 96-well format. Protein precipitation was achieved by quenching with acetonitrile (3:1 v/v). The Agilent 1260/1290 Infinity III LC system with hybrid multisampler and Feed Injection mode enabled direct injection of 75% organic samples with preserved chromatographic integrity. Separation used a Poroshell 120 EC-C18 column (2.1 × 100 mm, 2.7 µm) at 45 °C. Detection employed the Agilent Revident Q-TOF LC/MS (Dual Jet Stream source, m/z 50–1700) operated in positive ion mode. Data acquisition and processing utilized Agilent MassHunter software (acquisition version 12.1, Qualitative Analysis 13.0) and MassHunter Explorer 2.0 for feature finding, statistical filtering and targeted MS/MS. Structure elucidation was performed in SIRIUS 6.3.2 with CSI:FingerID, leveraging a custom BioTransformer-generated database of 1,946 predicted biotransformations and a small library of nine known verapamil metabolites.

Main results and discussion

The Feed Injection strategy outperformed classical flow-through injection for polar metabolite detection, maintaining peak shape and signal at injection volumes up to 20 µL without sample drying. MassHunter Explorer extracted 7,501 molecular features, and sequential volcano plot analyses (fold change > 5, p < 0.01 with Benjamini-Hochberg correction) narrowed these to 88 verapamil-related compounds. Directed MS/MS targeting these precursors generated high-quality fragmentation data with narrow retention time windows. Library searches in the Agilent Applied Markets PCDL confirmed verapamil and several known metabolites. SIRIUS with CSI:FingerID, constrained to the custom BioTransformer database and the small reference library, produced 27 high-confidence identifications (confidence score > 0.01). Notable assignments included:

• M26 as norverapamil, verified by authentic standard.
• M23 as p-O-desmethylverapamil, distinguished by diagnostic fingerprints.
• M4 and M10 as PR-25 and D-620, respectively, matching known metabolites sharing C16H24N2O2.

Integration of SIRIUS results back into MassHunter Explorer enabled visualization of metabolite formation over time, illustrating primary and secondary biotransformation kinetics.

Benefits and practical applications

This automated pipeline delivers:

• Minimal sample preparation and direct injection to accelerate throughput.
• Robust separation and detection of low-abundance metabolites via Feed Injection.
• Statistical prioritization of drug-related features, reducing manual curation.
• In silico structure prediction for metabolites absent in public libraries.

It is applicable to early drug discovery, QA/QC labs and industrial metabolite profiling.

Future trends and applications

Advances likely include real-time cloud-based metabolite annotation, expanded Phase II biotransformation modeling, integration of machine-learning approaches for spectral deconvolution and adaptation to other high-resolution MS platforms. Enhanced instrument-software interoperability and richer community databases will further streamline discovery of novel metabolites.

Conclusion

The described workflow, combining Agilent Revident Q-TOF LC/MS, MassHunter Explorer 2.0, SIRIUS with CSI:FingerID and BioTransformer, provides a powerful, scalable solution for untargeted drug metabolite identification. It reliably profiles known and novel metabolites with minimal manual effort and supports rapid decision-making in pharmaceutical research.

Reference

Application Note: Drug Metabolite Identification with a Streamlined Software Workflow Combining Agilent Revident Q-TOF LC/MS and MassHunter Explorer 2.0, Agilent Technologies, publication 5994-8867EN, 2026.